Buz Investors Best Biotech Stock 2017 The biotech industry is one of the more lucrative–if volatile–sectors around for heady investors.

4 Biotech Stocks to Watch This Quarter

36px) Fz(25px)--sm Fz(32px) Mb(17px)--sm Mb(20px) Mb(30px)--lg Ff($ff-primary) Lts($lspacing-md) Fw($fweight) Fsm($fsmoothing) Fsmw($fsmoothing) Fsmm($fsmoothing) Wow(bw)" data-reactid="3">4 Biotech Stocks to Watch This Quarter

Buz Investors Best Biotech Stock 2017 The biotech industry is one of the more lucrative–if volatile–sectors around for heady investors.

Biotech Stocks The biotech sector could easily continue to grow. Why? The long-term trends that have made the sector an outperformer in the market over the past five years remain in place. Biotechnology stocks continue to maintain a strong pace amid phase trials, new leadership and big investments from insiders.

Before the 2016 U.S. presidential election, the biotech industry itself was in a downward trend with many expecting Hillary Clinton to become president and put pressure on big pharma. Once President Trump took office, biotechnology stocks took on a much brighter spotlight. This has been clearly evidenced by the dramatic shift in the Nasdaq Biotechnology Index (NBI). The index itself has increased by as much as 33% after hitting new highs earlier in July.

In line with this, the Nasdaq Biotech Index (in blue, above) continues to outpace both the S&P500 (in green) and the Nasdaq (in red). The regulatory environment in the U.S. leans in favor of biotechnology, with the Food and Drug Administration offering fast-track approval for some breakthrough drugs, especially those targeting rare diseases.



Biotech Stocks

Oxis International Inc. (OXIS), for example, develops and commercializes innovative immunotherapeutics and has a robust portfolio. Oxis has a portfolio of next-generation cancer initiatives and its lead drug candidate, OXS-1550. In fact, the first patient has begun treatment in a FDA-approved Phase 2 clinical trial of its cancer therapy.

Dr. Daniel Vallera, director of the section on Molecular Cancer Therapeutics at the University of Minnesota Cancer Center, helped develop OXS-1550. He commented on the drug.

“The initiation of Phase 2 patient treatment is a key opportunity to demonstrate the effectiveness of this promising cancer therapy,” Vallera said. “This brings us one step closer to an important alternative to invasive chemotherapies and costly cell therapies, Kite Pharma, Inc. (KITE), Juno Therapeutics (JUNO), for cancer patients.”

Oxis recently announced it has signed a binding letter of intent agreement to acquire Georgetown Translational Pharmaceuticals Inc. Formal completion of this agreement will allow Oxis to acquire Georgetown Translational’s leading candidate, Pain Brake. This therapy is a pain relief drug expected to be submitted to the FDA as a new drug application in 15 to 18 months.

Dr. Kathleen Clarence-Smith, co-founder of Chase Pharmaceuticals Corp. (acquired by Allergan PLC (AGN)), will become the new CEO of Oxis and the company has also proposed a name change to GT Biopharma Inc. as part of the transaction.

Similar to Oxis, Moleculin Biotech Inc. (MBRX) also recently announced adding members to the company. In late July, Moleculin appointed John M. Climaco as an independent member of the board of directors.

“We are pleased to have John join our Board as he brings a wealth of international business successes managing complex operations in addition to his well-established capabilities in capital markets, product commercialization and business development,” Moleculin CEO Walter Klemp said.

Recently, the company has been focused on providing support to help jumpstart the launch of a physician-sponsored investigational new drug (IND) application to study the company’s WP1066. This drug is designed for the treatment of adult brain tumors (glioblastoma).

“By providing additional guidance and data, we think we can help accelerate the ability of the physician investigator to respond to FDA’s requests in a way that will allow the study to begin, which we believe could position WP1066 for a brain tumor trial this year,” Klemp said in a press release.

Moleculin share prices have jumped since late June to as high as $3.75. On July 31, the stock closed at $2.99, which was up over 100% since July 10.

Another biotech stock in focus is BioLineRX Ltd. (BLRX). The company is in its clinical stages and focusing on oncology and immunology. It is currently working on a combination trial of BL-8040 (the company’s lead oncology platform) and atezolizumab in order to develop a cancer immunotherapy combination. Genentech, a member of the Roche Group, has begun a Phase 1b/2 study for BL-8040 in order to evaluate the combination in metastatic pancreatic ductal adenocarcinoma.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



Marina Biotech up Thinly traded nano cap Marina Biotech (MRNA +10.6%) perks up after the company announced

Marina Biotech up 11% on SMARTICLES license deal

Marina Biotech up 11% on SMARTICLES license deal

Marina Biotech up Thinly traded nano cap Marina Biotech (MRNA +10.6%) perks up after the company announced

INVESTORS Marina Biotech up Thinly traded nano cap Marina Biotech (MRNA+10.6%) perks up after the company announced that it has out-licensed its SMARTICLES platform for the delivery of antisense DNA therapeutics to Oncotelic, a first for the company.




 

 

Marina Biotech up

 

Under the terms of the deal, Oncotelic will invest $250K in Marina via the purchase of common stock at $0.51/share. Subject to conditions, Marina may receive a commercial license fee via the sale of $500K of common shares to Oncotelic, in addition to sales-based milestones. Total potential sales milestones are capped at $90M. Additional financial terms are not disclosed.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



Buz Investors Best Biotech Stock 2017 The biotech industry is one of the more lucrative–if volatile–sectors around for heady investors.

Amgen Stock: The One Best Biotech Stock Play for 2017

Amgen Stock – the Best Biotech Stock 2017?

Buz Investors Best Biotech Stock 2017 The biotech industry is one of the more lucrative–if volatile–sectors around for heady investors.

Buz Investors Best Biotech Stock 2017  The biotech industry is one of the more lucrative–if volatile–sectors around for heady investors. With so much depending on government regulation, competition, and public opinion, there’s a lot of room to make big gains in the biotech industry, and a lot of room to see your money evaporate before you can say “Phase III approval.” That’s why it’s so important to find a solid company with both longevity and strong growth potential; otherwise, you might find yourself on the losing end of a biotech trade. For me, Amgen, Inc. (NASDAQ:AMGN) stock is the best biotech stock for 2017 for exactly the reasons mentioned above.

Amgen is among the world’s largest biotechnology firms, and as such, AMGN stock is one of the more valuable tickers on the market. One of its flagship treatments is “Neulasta,” two drugs used to prevent infections in patients undergoing cancer chemotherapy.



OTHER STORIES BUZ TRADERS SHARE

Best Biotech Stock 2017

It’s leading seller is “Enbrel,” a tumor necrosis factor blocker used to deal with rheumatoid arthritis and other autoimmune diseases. Both Enbrel and Neulasta account for over $1.0 billion each in sales and are strong propellants of the AMGN stock price.

New results from the “Repatha” (a heart medication) cardiovascular outcomes trial are forthcoming and likely to show positive results for the medication. Repatha was a big part of Amgen’s gains in the last year, growing from $10.0 million in sales during 2015 to $141.0 million in 2016. Being a newer drug, this coincides with the approval process of various government drug administrations, but shows promise for the company heading into 2017. (Source: “Amgen Highlights Landmark Repatha® (Evolocumab) Cardiovascular Outcomes Study Amongst Data To Be Presented At ACC.17,” Yahoo! Finance, March 6, 2017.)

The sales potential for Repatha is in the billions as heart disease is the leading cause of the death in the U.S. In fact, according to Centers for Disease Control and Prevention numbers, one if four deaths in the U.S. comes as a result of heart disease. The price, however, could present a barrier to adoption by insurance companies. (Source: “Heart Disease Facts,” Centers for Disease Control and Prevention, August 10, 2015.)

We have to get our drug industry coming back. Our drug industry has been disastrous, they’re leaving left and right. They supply our drugs but they don’t make them here, to a large extent,” Trump said during a press conference in January. “And the other thing we have to do is create new bidding procedures for the drug industry, because they’re getting away with murder.” (Source: “Trump says drugmakers are ‘getting away with murder,’ and biotech stocks plunge,” CNBC, January 11, 2017.)

Combine this with other problems in public perception, like infamous “Pharma Bro” Martin Shkreli and the various other scandals involving big pharmaceutical companies, and you have a climate that is certainly not friendly towards the biotech industry. One misstep can cost a company billions on the market, if they don’t play their cards right.


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Biotechnology Stocks: Tiny Biotech Stock Poised to Surge

Biotechnology Stocks: Tiny Biotech Stock Poised to Surge




Biotechnology Stocks: Tiny Biotech Stock Poised to Surge

  • Biotechnology stocks represent a great opportunity for investors who are fortunate enough to get into the right names at the right time.
  • Amphastar Pharmaceuticals Inc(NASDAQ:AMPH) stock represents the best of both worlds when it comes to a biotechnology stock. The company is both a developer and a gateway for generic drugs.
  • Shortly after breaking out of the triangle, AMPH stock generated a “golden cross” on May 27, 2016. A golden cross is a bullish signal that is produced when a 50-day moving average, highlighted in blue, crosses above a 200-day moving average,

The Next Big Biotech Stock? Maybe

Biotechnology Stocks: Tiny Biotech Stock Poised to Surge

Amphastar Pharmaceuticals Inc(NASDAQ:AMPH) stock represents the best of both worlds when it comes to a biotechnology stock. The company is both a developer and a gateway for generic drugs. This gives an investor some peace of mind as some of the risks associated with a biotech stock is diversified away. The business model is not the sole reason why I like this investment; I always look for companies that have constructive chart patterns that can help me discern the current trend.

Shortly after breaking out of the triangle, AMPH stock generated a “golden cross” on May 27, 2016. A golden cross is a bullish signal that is produced when a 50-day moving average, highlighted in blue, crosses above a 200-day moving average, highlighted in red. Investors use this signal to confirm that a bull market is on the horizon. It is always wise to trade in the direction of this signal. An investor holding a position should either be long or neutral after this signal is generated.

Two signals within the same month were suggesting and confirming that the consolidation had ended, and that the stock is free to trend higher. If that were not enough, one more signal has just recently reaffirmed the bullish bias, as the following chart illustrates.

n bull markets, the biotechnology stocks are amongst the best-performing sectors. It is not uncommon for investors in biotech stocks to experience windfall returns when the company they have invested in discovers a new medical breakthrough or receives FDA approval for a drug they have developed. AMPH stock represents the best of both worlds, as they are a reseller of generic drugs and develop their own. Throw in the bullish price chart and this investment has everything I need to make an informed investment decision.

VRX Stock: This Could Be the No. 1 Biotech Stock

VRX Stock: This Could Be the No. 1 Biotech Stock

VRX Stock: This Could Be the No. 1 Biotech Stock

  • Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has gained almost 14% this week on the New York Stock Exchange.
  • a former major Valeant Pharmaceutical shareholder, is suing the company’s former CEO Michael Pearson as well as other former and some current executives in New Jersey.
  • Valeant Pharmaceuticals, with its new CEO Joe Papa (an outsider when it comes to any of the accusations the company is facing), may eventually change its name if the reputation associated with its current brand interferes with its turnaround plan

 

VRX Stock May Face Bumpy Road, but Outlook is Bullish

VRX Stock: This Could Be the No. 1 Biotech Stock

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has gained almost 14% this week on the New York Stock Exchange. One of the factors contributing to the bullish sentiment over Valeant stock came from Morgan Stanley, which gave it an “overweight” recommendation and a price target boost from $33.00 to $42.00. The case for investing in Valeant is clear.

Valeant stock has some risks, and the risk of legal problems popping up over its previous association with the now discredited Philidor Rx Services. But the upward, or bullish if you will, potential is more attractive than Valeant is risky. This company has a simple but effective strategy for recovery, focused on reducing its debt while continuing to pursue new potential blockbuster drugs. Besides, the pharmaceuticals company can always rely on the sale of valuable assets to improve its position if necessary.

Former major investors will certainly put some speed bumps along the path to recovery, but they will be temporary and surmountable. Indeed, it did not take long for Valeant to find a speed bump putting pressure on its shares, even as it still shows strong gains for the past week. T. Rowe Price Group Inc, a mutual fund, and a former major Valeant Pharmaceutical shareholder, is suing the company’s former CEO Michael Pearson as well as other former and some current executives in New Jersey. (Source: “Valeant Pharmaceuticals International Inc sued for fraud by T. Rowe Price Group,” Financial Post, August18, 2016.)

The plaintiff has accused the company of having adopted a “fraudulent business model” that allegedly has cost investors billions of dollars. The situation is not new. Others have also accused the company of allegedly practicing deceptive pricing and questionable accounting policies. T. Rowe sold a majority of its Valeant stock last May and now it seeks compensation.

Valeant Pharmaceuticals, with its new CEO Joe Papa (an outsider when it comes to any of the accusations the company is facing), may eventually change its name if the reputation associated with its current brand interferes with its turnaround plan. (Source: “New Valeant CEO continues his executive shakeup,” The Globe and Mail, August 8, 2016.) Papa is simply taking it in stride, pushing ahead because the company he now manages has already made progress.